319 related articles for article (PubMed ID: 24974129)
1. Therapeutic targeting of integrin αvβ6 in breast cancer.
Moore KM; Thomas GJ; Duffy SW; Warwick J; Gabe R; Chou P; Ellis IO; Green AR; Haider S; Brouilette K; Saha A; Vallath S; Bowen R; Chelala C; Eccles D; Tapper WJ; Thompson AM; Quinlan P; Jordan L; Gillett C; Brentnall A; Violette S; Weinreb PH; Kendrew J; Barry ST; Hart IR; Jones JL; Marshall JF
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 24974129
[TBL] [Abstract][Full Text] [Related]
2. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.
Reader CS; Vallath S; Steele CW; Haider S; Brentnall A; Desai A; Moore KM; Jamieson NB; Chang D; Bailey P; Scarpa A; Lawlor R; Chelala C; Keyse SM; Biankin A; Morton JP; Evans TJ; Barry ST; Sansom OJ; Kocher HM; Marshall JF
J Pathol; 2019 Nov; 249(3):332-342. PubMed ID: 31259422
[TBL] [Abstract][Full Text] [Related]
3. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
Desai K; Aiyappa R; Prabhu JS; Nair MG; Lawrence PV; Korlimarla A; Ce A; Alexander A; Kaluve RS; Manjunath S; Correa M; Srinath BS; Patil S; Kalamdani A; Prasad M; Sridhar TS
Tumour Biol; 2017 Mar; 39(3):1010428317695028. PubMed ID: 28349782
[TBL] [Abstract][Full Text] [Related]
4. A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.
Eberlein C; Kendrew J; McDaid K; Alfred A; Kang JS; Jacobs VN; Ross SJ; Rooney C; Smith NR; Rinkenberger J; Cao A; Churchman A; Marshall JF; Weir HM; Bedian V; Blakey DC; Foltz IN; Barry ST
Oncogene; 2013 Sep; 32(37):4406-16. PubMed ID: 23108397
[TBL] [Abstract][Full Text] [Related]
5. High expression of integrin β6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers.
Desai K; Nair MG; Prabhu JS; Vinod A; Korlimarla A; Rajarajan S; Aiyappa R; Kaluve RS; Alexander A; Hari PS; Mukherjee G; Kumar RV; Manjunath S; Correa M; Srinath BS; Patil S; Prasad MS; Gopinath KS; Rao RN; Violette SM; Weinreb PH; Sridhar TS
Cancer Med; 2016 Aug; 5(8):2000-11. PubMed ID: 27184932
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
7. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
[TBL] [Abstract][Full Text] [Related]
8. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
[TBL] [Abstract][Full Text] [Related]
9. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.
Parra-Palau JL; Morancho B; Peg V; Escorihuela M; Scaltriti M; Vicario R; Zacarias-Fluck M; Pedersen K; Pandiella A; Nuciforo P; Serra V; Cortés J; Baselga J; Perou CM; Prat A; Rubio IT; Arribas J
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25253614
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
12. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
[TBL] [Abstract][Full Text] [Related]
13. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Kodack DP; Chung E; Yamashita H; Incio J; Duyverman AM; Song Y; Farrar CT; Huang Y; Ager E; Kamoun W; Goel S; Snuderl M; Lussiez A; Hiddingh L; Mahmood S; Tannous BA; Eichler AF; Fukumura D; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3119-27. PubMed ID: 23071298
[TBL] [Abstract][Full Text] [Related]
14. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
[TBL] [Abstract][Full Text] [Related]
15. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
16. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
18. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
19. An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
Chen Q; Weng Z; Lu Y; Jia Y; Ding L; Bai F; Ge M; Lin Q; Wu K
PLoS One; 2017; 12(1):e0168960. PubMed ID: 28045951
[TBL] [Abstract][Full Text] [Related]
20. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
